Consequently, this could provide novel application approaches for PAD inhibition in autoimmune diseases, cancer, as well as in neurological conditions, where Cl-amidine has previously been shown to be neuroprotective in CNS injury [6,7]. This evidence concerns the gene PADI4 and autoimmune disease.